Aurobindo Pharma partners with BIRAC to develop Covid-19 vaccine
Aurobindo Pharma is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. The vaccine candidate is based on a... Read More
Insight on First approved COVID-19 vaccine Sputnik V
Posted on11 Aug 2020
Comments0
Russia has announced the launch of first approved covid-19 vaccine. The Covid-19 vaccine brand name is Sputnik V. Sputnik V is developed... Read More
Lupin gets exclusive rights to market and distribute 2 complex injectable assets from ForDoz Pharma
Pharma major Lupin Limited announced that its US based wholly-owned subsidiary Lupin Pharmaceuticals Inc., has entered into an agreement with ForDoz Pharma... Read More
Zydus Cadila’s ZyCoV-D in Phase II clinical trials for COVID-19
Zydus Cadila’s ZyCoV-D is the plasmid DNA vaccine to prevent COVID-19. ZyCoV-D was found to be safe and well tolerated in the... Read More
Lynk Pharmaceuticals enters exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA
Lynk Pharmaceuticals (Hangzhou, China) is pleased to announce exclusive licensing agreements with Kobe University (Kobe, Japan) and with RIKEN Research Institute (Saitama,... Read More
Novavax, FDB agreement for large scale manufacturing of COVID-19 vaccine candidate
Posted on28 Jul 2020
Comments0
NovavaxInc, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading CDMO for... Read More
Pfizer-BioNTech agreement with U.S. Gov for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the... Read More
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based SARS-CoV-2 vaccine
Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against... Read More
AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins... Read More
Market Exclusivity Case Study: XIFAXAN (rifaximin)
Posted on07 May 2020
Comments0
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, which is one of the largest specialty pharmaceutical companies in... Read More